200 ML immunoglobulin G, human 50 MG/ML Injection [Gammaplex]

What the CMS Formulary Data Shows for 200 ML immunoglobulin G, human 50 MG/ML Injection [Gammaplex]

Per the CMS 2026 Part D formulary file, 200 ML immunoglobulin G, human 50 MG/ML Injection [Gammaplex] (RxNorm concept RXCUI 1809513, generic name immunoglobulin G, human) appears on 106 distinct formulary files spanning 1,173 Medicare Part D plan offerings - 23.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 4.2.

Real-world access to 200 ML immunoglobulin G, human 50 MG/ML Injection [Gammaplex] depends on utilization management as much as tier placement: 98.1% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 40 Part D beneficiaries filled 200 ML immunoglobulin G, human 50 MG/ML Injection [Gammaplex] in 2023, with total plan-and-beneficiary spending of $5,071,918 and an average per-beneficiary annual cost of $126,797.94. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 200 ML immunoglobulin G, human 50 MG/ML Injection [Gammaplex] today.